R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-12-20
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of lenalidomide when given
together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) and to see how well they
work in treating patients with diffuse large B-cell lymphoma that has returned after a period
of improvement (relapsed) and that has not responded to previous treatment (refractory).
Drugs used in chemotherapy, such as rituximab, ifosfamide, carboplatin, etoposide, and
lenalidomide, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
lenalidomide with R-ICE may be a better treatment for patients with diffuse large B-cell
lymphoma.